Joep J. de Jong - Concepedia

Author

Joep J. de Jong

Also Known As

J J De Jong, J. J. de Jong, J.J. De Jong, J.J. Jong, J.J. de Jong, J.J.D. Jong, Jae Jun Jong, Joep J de Jong, Joep J. de Jong

Publications

884

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Cancer Institute Erasmus MC University of British Columbia Decipher Biosciences (Canada)The Netherlands Cancer Institute

About

Joep J. de Jong is an author at Erasmus MC Cancer Institute specializing in urology, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	379
2	Pathology	5	5	180
3	Cancer Therapeutics	2	2	207
4	Immunology	1	1	172
5	Cancer Genetics	1	1	43

Joep J. de Jong

Publications

719

Citations

H-Index

Page 1

	Year	Citations
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer Andrea Necchi, Daniele Raggi, Andrea Gallina, European Urology Molecular SubtypingUrologyGenitourinary CancerMedicineImmunology	2020	172
Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis Joep J. de Jong, Yang Liu, A. Gordon Robertson, Genome Medicine	2019	89
Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients Joep J. de Jong, Kees Hendricksen, Marloes Rosier, Bladder Cancer	2018	72
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences Joep J. de Jong, Joost L. Boormans, Bas W.G. van Rhijn, European Urology Oncology UrologyMolecular SubtypesGenitourinary CancerTumor HeterogeneityMedicine	2020	43
Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer Vera Genitsch, Attila Kollár, Gillian Vandekerkhove, Urologic Oncology Seminars and Original Investigations UrologyTumoral PathologyGenitourinary CancerTumor HeterogeneityPathology	2019	43
Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer Vera Genitsch, Attila Kollár, Gillian Vandekerkhove, Urologic Oncology Seminars and Original Investigations UrologyTumoral PathologyGenitourinary CancerTumor HeterogeneityPathology	2019	41
Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer Olga M Pijpers, Kees Hendricksen, Hugh Mostafid, Urologic Oncology Seminars and Original Investigations	2021	38
Concordance of <scp>PD</scp>‐L1 expression in matched urothelial bladder cancer specimens Joep J. de Jong, Hans Stoop, Daan Nieboer, Histopathology	2018	36
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study Andrea Necchi, Daniele Raggi, Patrizia Giannatempo, European Urology Oncology UrologyGenitourinary CancerMedicinePathologyMuscle-invasive Bladder Cancer	2020	35
Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria Solomon L. Woldu, Casey K. Ng, Ronald K. Loo, The Journal of Urology	2020	28

Page 1